Your browser doesn't support javascript.
loading
The landscape of metabolic brain alterations in Alzheimer's disease.
Batra, Richa; Arnold, Matthias; Wörheide, Maria A; Allen, Mariet; Wang, Xue; Blach, Colette; Levey, Allan I; Seyfried, Nicholas T; Ertekin-Taner, Nilüfer; Bennett, David A; Kastenmüller, Gabi; Kaddurah-Daouk, Rima F; Krumsiek, Jan.
Afiliación
  • Batra R; Department of Physiology and Biophysics, Institute for Computational Biomedicine, Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, New York, USA.
  • Arnold M; Department of Psychiatry and Behavioral Sciences, Duke University, Durham, North Carolina, USA.
  • Wörheide MA; Institute of Computational Biology, Helmholtz Zentrum München-German Research Center for Environmental Health, Neuherberg, Germany.
  • Allen M; Institute of Computational Biology, Helmholtz Zentrum München-German Research Center for Environmental Health, Neuherberg, Germany.
  • Wang X; Department of Neuroscience, Mayo Clinic Florida, Jacksonville, Florida, USA.
  • Blach C; Department of Health Sciences Research, Mayo Clinic Florida, Jacksonville, Florida, USA.
  • Levey AI; Department of Psychiatry and Behavioral Sciences, Duke University, Durham, North Carolina, USA.
  • Seyfried NT; Goizueta Alzheimer's Disease Research Center, Emory University, Atlanta, Georgia, USA.
  • Ertekin-Taner N; Department of Biochemistry, Emory School of Medicine, Jacksonville, Florida, USA.
  • Bennett DA; Department of Neuroscience, Mayo Clinic Florida, Jacksonville, Florida, USA.
  • Kastenmüller G; Department of Neurology, Mayo Clinic Florida, Jacksonville, Florida, USA.
  • Kaddurah-Daouk RF; Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois, USA.
  • Krumsiek J; Institute of Computational Biology, Helmholtz Zentrum München-German Research Center for Environmental Health, Neuherberg, Germany.
Alzheimers Dement ; 2022 Jul 13.
Article en En | MEDLINE | ID: mdl-35829654
INTRODUCTION: Alzheimer's disease (AD) is accompanied by metabolic alterations both in the periphery and the central nervous system. However, so far, a global view of AD-associated metabolic changes in the brain has been missing. METHODS: We metabolically profiled 500 samples from the dorsolateral prefrontal cortex. Metabolite levels were correlated with eight clinical parameters, covering both late-life cognitive performance and AD neuropathology measures. RESULTS: We observed widespread metabolic dysregulation associated with AD, spanning 298 metabolites from various AD-relevant pathways. These included alterations to bioenergetics, cholesterol metabolism, neuroinflammation, and metabolic consequences of neurotransmitter ratio imbalances. Our findings further suggest impaired osmoregulation as a potential pathomechanism in AD. Finally, inspecting the interplay of proteinopathies provided evidence that metabolic associations were largely driven by tau pathology rather than amyloid beta pathology. DISCUSSION: This work provides a comprehensive reference map of metabolic brain changes in AD that lays the foundation for future mechanistic follow-up studies.
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Alzheimers Dement Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Alzheimers Dement Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos